Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Pursuing Generic Biologics; Says Brand And Generic Lines Co-Exist

Executive Summary

Novartis is positioning itself at the forefront of companies seeking approval of generic biologics with a pending application for human growth hormone

You may also be interested in...



Sandoz Gets New Leader: Is Restructuring Next For Novartis’ Generics Unit?

Novartis is focusing on operational efficiencies in its Sandoz generics business to address a difficult pricing environment in the U.S

Sandoz Gets New Leader: Is Restructuring Next For Novartis’ Generics Unit?

Novartis is focusing on operational efficiencies in its Sandoz generics business to address a difficult pricing environment in the U.S

Sandoz Omnitrope NDA Is Test For Follow-On Biologics; Pfizer Says No

Sandoz' pending NDA for Omnitrope appears ripe for an FDA decision

Related Content

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel